So I think the things you bring up are more like the monoclonal antibodies instead of CV. But I asked you as to what your experience is as you stated you were a clinician. Sincere questions. When in the disease course are you giving convalescent plasma and what has been the outcomes?
I am relatively impressed with bamlanivimab and combination monoclonals. I have seen these work pretty well. Is this not a better modality than convalescent plasma?
The rest is just noise, good or bad.
Just be sure what you know, is.
Lives depend on it.
Personally, what i would rather do would be a thin tome.